Paul Workman

List of Publications by Year
in descending order

83 papers	11,353 citations	44069 48 h-index	56724 83 g-index
90 all docs	90 docs citations	90 times ranked	17158 citing authors

#	Article	IF	Citations
1	Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359, 920-926.	12.6	1,199
2	Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 2012, 30, 679-692.	17.5	883
3	Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?. Clinical Cancer Research, 2012, 18, 64-76.	7.0	855
4	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	8.0	698
5	Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies. Journal of Clinical Oncology, 2005, 23, 4152-4161.	1.6	479
6	NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis. Cancer Research, 2008, 68, 2850-2860.	0.9	433
7	4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer. Journal of Medicinal Chemistry, 2008, 51, 196-218.	6.4	386
8	Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis. Cancer Cell, 2008, 14, 250-262.	16.8	291
9	Inhibitors of cyclin-dependent kinases as cancer therapeutics. , 2017, 173, 83-105.		278
10	First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Panâ€“Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2015, 21, 77-86.	7.0	265
11	Envisioning the future of early anticancer drug development. Nature Reviews Cancer, 2010, 10, 514-523.	28.4	262
12	Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular Cancer Therapeutics, 2009, 8, 1725-1738.	4.1	253
13	Probing the Probes: Fitness Factors For Small Molecule Tools. Chemistry and Biology, 2010, 17, 561-577.	6.0	253
14	Novel, Potent Small-Molecule Inhibitors of the Molecular Chaperone Hsp90 Discovered through Structure-Based Design. Journal of Medicinal Chemistry, 2005, 48, 4212-4215.	6.4	232
15	The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3338-3343.	2.2	228
16	The Cyclin-dependent Kinase Inhibitor CYC202 (R-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway. Cancer Research, 2004, 64, 262-272.	0.9	187
17	Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology. Cancer Cell, 2017, 32, 9-25.	16.8	183
18	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	21.4	182

#	Article	IF	Citations
19	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors. Clinical Cancer Research, 2011, 17, 1561-1570.	7.0	178
20	Maximizing the Therapeutic Potential of HSP90 Inhibitors. Molecular Cancer Research, 2015, 13, 1445-1451.	3.4	161
21	Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Molecular Cancer Therapeutics, 2007, 6, 1198-1211.	4.1	141
22	A public-private partnership to unlock the untargeted kinome. Nature Chemical Biology, 2013, 9, 3-6.	8.0	141
23	How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development. Current Pharmaceutical Design, 2003, 9, 891-902.	1.9	141
24	ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nature Chemical Biology, 2013, 9, 307-312.	8.0	132
25	A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature Chemical Biology, 2015, 11, 973-980.	8.0	114
26	In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. Cancer Research, 2007, 67, 2206-2216.	0.9	111
27	Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 2013, 12, 35-50.	46.4	111
28	Drug discovery in advanced prostate cancer: translating biology into therapy. Nature Reviews Drug Discovery, 2016, 15, 699-718.	46.4	111
29	HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discovery Today, 2012, 17, 242-252.	6.4	101
30	A Useful Approach to Identify Novel Small-Molecule Inhibitors of Wnt-Dependent Transcription. Cancer Research, 2010, 70, 5963-5973.	0.9	96
31	Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology, 2012, 52, 549-573.	9.4	96
32	MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, 2018, 154, 1066-1079.e5.	1.3	94
33	Death by chaperone: HSP90, HSP70 or both?. Cell Cycle, 2009, 8, 518-526.	2.6	93
34	Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. Journal of Medicinal Chemistry, 2016, 59, 1078-1101.	6.4	89
35	Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766). Journal of Medicinal Chemistry, 2018, 61, 918-933.	6.4	81
36	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. Cancer Research, 2016, 76, 2731-2742.	0.9	79

#	Article	IF	Citations
37	Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut, 2017, 66, 1268-1277.	12.1	75
38	Structure-based drug design: aiming for a perfect fit. Essays in Biochemistry, 2017, 61, 431-437.	4.7	75
39	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2019, 47, D917-D922.	14.5	75
40	How Much Longer Will We Put Up With $100,000 Cancer Drugs?. Cell, 2017, 168, 579-583.	28.9	74
41	Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chemical Biology, 2018, 25, 194-205.e5.	5.2	71
42	Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discovery Today, 2010, 15, 88-97.	6.4	69
43	Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. ELife, 2016, 5, .	6.0	69
44	The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585.	3.3	68
45	Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen. Journal of Medicinal Chemistry, 2015, 58, 1717-1735.	6.4	65
46	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current Pharmaceutical Design, 2017, 22, 6935-6945.	1.9	65
47	Critical parameters in targeted drug development: the pharmacological audit trail. Seminars in Oncology, 2016, 43, 436-445.	2.2	64
48	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2021, 49, D1074-D1082.	14.5	63
49	Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Molecular Cancer Therapeutics, 2003, 2, 131-8.	4.1	63
50	Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. PLoS ONE, 2020, 15, e0234103.	2.5	50
51	Drugging cancer genomes. Nature Reviews Drug Discovery, 2013, 12, 889-890.	46.4	47
52	Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen. Journal of Medicinal Chemistry, 2017, 60, 180-201.	6.4	47
53	Distinctive Behaviors of Druggable Proteins in Cellular Networks. PLoS Computational Biology, 2015, 11, e1004597.	3.2	43
54	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	8.2	40

#	Article	IF	Citations
55	2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. ACS Medicinal Chemistry Letters, 2016, 7, 573-578.	2.8	39
56	Target 2035 â€“ update on the quest for a probe for every protein. RSC Medicinal Chemistry, 2022, 13, 13-21.	3.9	39
57	CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells. Cancer Research, 2020, 80, 1735-1747.	0.9	38
58	Drugging the heat shock factor 1 pathway: Exploitation of the critical cancer cell dependence on the guardian of the proteome. Cell Cycle, 2009, 8, 3806-3808.	2.6	35
59	Molecular profiling and combinatorial activity of <scp>CCT</scp>068127: a potent <scp>CDK</scp>2 and <scp>CDK</scp>9 inhibitor. Molecular Oncology, 2018, 12, 287-304.	4.6	33
60	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Bioorganic and Medicinal Chemistry, 2011, 19, 6949-6965.	3.0	31
61	Modulation of Biliary Cancer Chemoâ€Resistance Through MicroRNAâ€Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology, 2020, 72, 982-996.	7.3	30
62	Exploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70. Journal of Medicinal Chemistry, 2016, 59, 4625-4636.	6.4	29
63	Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene, 2019, 38, 5076-5090.	5.9	26
64	HER3 Is an Actionable Target in Advanced Prostate Cancer. Cancer Research, 2021, 81, 6207-6218.	0.9	25
65	Public resources for chemical probes: the journey so far and the road ahead. Future Medicinal Chemistry, 2021, 13, 731-747.	2.3	24
66	Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases. Oncogene, 2019, 38, 5905-5920.	5.9	23
67	Transforming cancer drug discovery with Big Data and AI. Expert Opinion on Drug Discovery, 2019, 14, 1089-1095.	5.0	22
68	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. Clinical Cancer Research, 2019, 25, 4624-4633.	7.0	21
69	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget, 2013, 4, 1647-1661.	1.8	20
70	Discovery of 4,6-disubstituted pyrimidines as potent inhibitors of the heat shock factor 1 (HSF1) stress pathway and CDK9. MedChemComm, 2016, 7, 1580-1586.	3.4	19
71	Reflections and Outlook on Targeting HSP90, HSP70 and HSF1 in Cancer: A Personal Perspective. Advances in Experimental Medicine and Biology, 2020, 1243, 163-179.	1.6	18
72	Privileged Structures and Polypharmacology within and between Protein Families. ACS Medicinal Chemistry Letters, 2018, 9, 1199-1204.	2.8	16

#	Article	IF	Citations
73	A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2. Trends in Pharmacological Sciences, 2021, 42, 313-315.	8.7	16
74	Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3.	5.2	13
75	From patent to patient: analysing access to innovative cancer drugs. Drug Discovery Today, 2020, 25, 1561-1568.	6.4	11
76	Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development. Nature Reviews Clinical Oncology, 2021, 18, 454-467.	27.6	11
77	Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, 2016, 7, 3658-3661.	1.8	11
78	Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Nature Communications, 2021, 12, 6738.	12.8	10
79	The pharmacological audit trail (PhAT): Use of tumor models to address critical issues in the preclinical development of targeted anticancer drugs. Drug Discovery Today: Disease Models, 2016, 21, 23-32.	1.2	8
80	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. Scientific Reports, 2020, 10, 16000.	3.3	8
81	Structural and functional characterisation of human RNA helicase DHX8 provides insights into the mechanism of RNA-stimulated ADP release. Biochemical Journal, 2019, 476, 2521-2543.	3.7	6
82	Using biomarkers in drug development. Clinical Advances in Hematology and Oncology, 2006, 4, 736-9.	0.3	5
83	Enhancing access to innovative cancer drugs: Cross-sector consensus on a way forward to benefit patients. Drug Discovery Today, 2022, 27, 946-950.	6.4	1